TIGIT is elevated in gastric cancer patients, where it may regulate the metabolic immune efficacy of CD8+ T cells, and the synergistic blockade of TIGIT and programmed death receptor-1 (PD-1) promoted the immune efficacy of CD8+ T cells [11]. Here, TIGIT is linked to gastric cancer.